Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for chronic inducible cold urticaria inadequately controlled by H1-antihistamines
jRCT2061200063Completed
- Sponsor
- Sanofi
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in Cold urticaria (CU) comparing Dupilumab + non-sedating H1-antihistamine with Placebo + non-sedating H1-antihistamine (2 arms). Primary endpoint: Proportion of participants with negative ice cube provocation test at Week 24. Started Jul 2021; status: completed.
02
Drugs
03
Conditions
Cold urticaria (CU)
Beyond the preview
Go deeper on jRCT2061200063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061200063.